Most companies of this size and nature are terrible at IR and understanding how to handle investors. What they have going for them is the technology. Unlike most though... hopefully they can outlast the market negativity long enough to deliver. That's always the question. Especially for biotechnology. Many great ideas but they can't survive the market. I am hoping ONVO does. But the risk is reflected in the PPS. No games, no agendas. Just the reality that there is much uncertainty. Why not take advantage?
News 
Market Data 
Discover 
